Sygnature Discovery
The Discovery Building Biocity, Pennyfoot Street, Nottingham, Nottinghamshire, NG1 1GR, United Kingdom
Overview
Sygnature Discovery is an independent provider of integrated drug discovery resource and expertise. It undertakes hit identification, hit-to-lead and lead optimization projects, and complete drug discovery programs. Core capabilities include medicinal chemistry, in vitro bioscience, computational sciences and informatics, DMPK/physical sciences, and project management. Sygnature operates from state of the art facilities in Nottingham and employs over 200 staff, most of whom are PhD scientists.
- Total investments
- 1
- Lead investments
- 0
- Investments · 12mo
- 0
- Active investors
- 0
Sector focus
- Biotechnology
Investment portfolio
- Step Pharma
Participated · Series A · Nov 2017
Founded in 2014, Step Pharma is pioneering inhibition of cytidine triphosphate synthetase-1 (CTPS1) to create highly selective cancer therapies that spare healthy tissue. Its lead compound, dencatistat, is in a phase 1a dose-escalation study for solid tumours and is also being tested in a phase 1/2 trial for relapsed or refractory T- and B-cell lymphoma, an indication for which it holds FDA orphan-drug designation. A third clinical programme is underway in essential thrombocythaemia, and phase 1b expansion cohorts for CTPS2-null ovarian and endometrial cancers are slated to begin enrolling in 2026, with a lung-cancer cohort planned. CTPS2 loss occurs in roughly 15-20 % of these gynaecological tumours, creating a synthetic-lethal dependency on CTPS1 that dencatistat is designed to exploit. Proceeds from recent financing will also fund drug manufacture and pivotal toxicology ahead of phase 2 studies. Headquartered in Saint-Genis-Pouilly, France, the company is backed by investors such as Kurma Partners, V-Bio Ventures, Bpifrance, Pontifax, Hadean Ventures, Sunstone Life Science Ventures and others, and it closed a €38 million Series C round in October 2025.
Team
No current team members are available.